Rebecca B. Klisovic

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation

Richard M. Stone, Sumithra J. Mandrekar, Ben L. Sanford et al. · New England Journal of Medicine · 2017 · 2.1K citations · Full text

Clinical response and <i>miR-29b</i> predictive significance in older AML patients treated with a 10-day schedule of decitabine

William Blum, Ramiro Garzon, Rebecca B. Klisovic et al. · Proceedings of the National Academy of Sciences · 2010 · 453 citations · Full text

Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia

William Blum, Rebecca B. Klisovic, Bjoern Hackanson et al. · Journal of Clinical Oncology · 2007 · 319 citations

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

Daniel J. DeAngelo, Richard M. Stone, Mark Heaney et al. · Blood · 2006 · 274 citations · Full text

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia

Parvathi Ranganathan, Xueyan Yu, Caroline Na et al. · Blood · 2012 · 240 citations · Full text